Chemours (NYSE:CC) Posts Earnings Results, Misses Expectations By $0.05 EPS

Chemours (NYSE:CC) announced its earnings results on Monday. The specialty chemicals company reported $0.21 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.05), FiscalAI reports. The firm had revenue of $1.54 billion for the quarter, compared to analyst estimates of $1.53 billion. Chemours had a positive return on equity of 60.64% and a negative net margin of 5.00%. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter last year, the business earned $0.40 EPS.

Chemours Stock Performance

Shares of NYSE:CC opened at $13.20 on Tuesday. The business has a 50-day moving average price of $14.17 and a two-hundred day moving average price of $18.26. Chemours has a 1-year low of $10.44 and a 1-year high of $28.67. The stock has a market capitalization of $1.99 billion, a P/E ratio of -6.91 and a beta of 1.41. The company has a current ratio of 1.66, a quick ratio of 0.88 and a debt-to-equity ratio of 18.98.

Chemours Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 15th. Shareholders of record on Monday, November 16th will be issued a dividend of $0.0875 per share. This represents a $0.35 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Monday, November 16th. Chemours’s payout ratio is currently -18.32%.

Key Chemours News

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours launched its Faizeon two-phase liquid-cooling portfolio for AI, high-performance computing and high-density data centers. The products are designed to manage rising heat loads while reducing energy and water consumption, giving the company potential exposure to the rapidly expanding AI infrastructure market. Chemours Launches Faizeon Two-Phase Liquid Cooling Solutions for AI Data Centers
• Positive Sentiment: A Seeking Alpha analysis upgraded Chemours, arguing that patient investors could be rewarded as the company executes on its portfolio and longer-term opportunities. The upgrade offers some support for the stock, although it does not immediately change the company’s earnings outlook. Chemours: Patient Investors Can Be Rewarded
• Neutral Sentiment: Chemours reported third-quarter revenue of $1.54 billion, up 3% year over year and slightly above the $1.53 billion analyst estimate. The company’s adjusted earnings per share of $0.21, however, fell short of the $0.26 consensus and declined from $0.40 a year earlier. The Chemours Company Reports Third Quarter Results
• Negative Sentiment: Multiple law firms announced or promoted a securities-fraud class action alleging Chemours and certain executives misrepresented demand for Opteon products before a major stock decline and a reduction in company guidance. The allegations have not been proven, but the litigation creates legal, reputational and potential financial risks. Investors seeking lead-plaintiff status face a December 7, 2026 deadline. CC Shareholder Notice

Analyst Ratings Changes

A number of research firms have recently issued reports on CC. Zacks Research upgraded shares of Chemours from a “strong sell” rating to a “hold” rating in a research note on Thursday, September 10th. The Goldman Sachs Group restated a “neutral” rating and set a $16.00 price target on shares of Chemours in a research report on Friday, October 9th. Weiss Ratings cut Chemours from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, August 6th. Truist Financial dropped their price target on Chemours from $24.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, October 20th. Finally, Barclays assumed coverage on Chemours in a research report on Monday, October 12th. They issued an “equal weight” rating and a $16.00 price objective for the company. Three equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Chemours has a consensus rating of “Hold” and a consensus target price of $17.73.

Insider Activity

In other news, CFO Shane Hostetter bought 3,350 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were bought at an average cost of $14.94 per share, for a total transaction of $50,049.00. Following the completion of the acquisition, the chief financial officer owned 102,698 shares in the company, valued at approximately $1,534,308.12. This trade represents a 3.37% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Calderon Gerardo Familiar bought 1,935 shares of Chemours stock in a transaction on Wednesday, August 12th. The shares were acquired at an average price of $15.53 per share, for a total transaction of $30,050.55. Following the completion of the acquisition, the insider owned 58,547 shares of the company’s stock, valued at approximately $909,234.91. This represents a 3.42% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 8,663 shares of company stock valued at $130,601 in the last 90 days. 0.85% of the stock is owned by company insiders.

Chemours Company Profile

The Chemours Company (NYSE: CC) is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.